FDA official warns of potential Ketek danger to children

06/8/2006 | NYTimes.com

An FDA official reportedly has urged a halt to clinical trials of Sanofi-Aventis' antibiotic Ketek for possible use in children because of potentially fatal side effects. More than 4,000 infants and children in a dozen countries are involved in trials to determine if Ketek, approved only for adults, is effective in treating children's ear infections and tonsillitis. The drug has been reported to cause problems, including loss of consciousness and liver failure, in adults.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA